Stockscreener 앱 받기
16.08
0.09%
0.015
시장 영업 전:
15.47
-0.61
-3.79%
전일 마감가:
$16.07
열려 있는:
$16.19
하루 거래량:
9.40M
Relative Volume:
1.06
시가총액:
$18.52B
수익:
$14.33B
순이익/손실:
$-3.79B
주가수익비율:
-5.0726
EPS:
-3.17
순현금흐름:
$1.84B
1주 성능:
+0.19%
1개월 성능:
+21.73%
6개월 성능:
+52.42%
1년 성능:
+40.07%
1일 변동 폭
$15.96
$16.47
1주일 범위
$15.73
$16.47
52주 변동 폭
$6.85
$16.47
비아트리스 Stock (VTRS) Company Profile
명칭
Viatris Inc
전화
(724) 514-1465
주소
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
16.08 | 18.50B | 14.33B | -3.79B | 1.84B | -3.17 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.61 | 58.92B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
128.95 | 54.31B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.44 | 49.34B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.62 | 39.50B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
535.10 | 20.38B | 3.13B | 1.27B | 1.12B | 26.39 |
비아트리스 Stock (VTRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-09 | 업그레이드 | UBS | Neutral → Buy |
| 2026-01-16 | 업그레이드 | Argus | Hold → Buy |
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-10-15 | 개시 | Truist | Buy |
| 2025-06-06 | 개시 | Goldman | Neutral |
| 2024-07-19 | 재개 | Jefferies | Buy |
| 2023-10-23 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-06-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2023-04-24 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2023-02-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-11-10 | 업그레이드 | UBS | Sell → Neutral |
| 2022-11-08 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | 재개 | Jefferies | Hold |
| 2022-06-14 | 개시 | UBS | Sell |
| 2022-05-10 | 다운그레이드 | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | 개시 | Citigroup | Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-03-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-03-02 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-02-26 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | 개시 | Argus | Hold |
| 2020-12-14 | 개시 | Bernstein | Mkt Perform |
모두보기
비아트리스 주식(VTRS)의 최신 뉴스
Viatris Inc. Stock Nears 52-Week High Ahead of Q4 Earnings: Shares Climb on Pipeline Strength - International Business Times Australia
Key facts: FDA Accepts Viatris' MR-141 Application; Q4 Results Due Soon - TradingView
Investors await Viatris earnings amid cost-cutting optimism By Investing.com - Investing.com
Viatris Q4 2025 Earnings Preview: Revenue Forecast & Analyst ExpectationsNews and Statistics - IndexBox
Analysts optimistic ahead of Viatris' Q4 earnings driven by healthy drugs pipeline - Seeking Alpha
FDA accepts Viatris presbyopia treatment application - Investing.com
Viatris, Opus gain as FDA to review label expansion for eyecare drug - Seeking Alpha
FDA Accepts Viatris Inc. Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia - marketscreener.com
FDA accepts Viatris supplemental new drug application for Mr-141 (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia - marketscreener.com
FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia - The AI Journal
FDA Accepts Viatris Supplemental New Drug Application For Mr-141 (Phentolamine Ophthalmic Solution 0.75%) For The Treatment Of Presbyopia - TradingView
Earnings To Watch: Viatris (VTRS) Reports Q4 Results Tomorrow - Yahoo Finance UK
Viatris stock hits 52-week high at $16.31 - Investing.com
Viatris (BIT:1VTRS) Price Target Increased by 12.32% to 11.92 - Nasdaq
Will UBS Upgrade And Inpefa’s First Global Launch Change Viatris' (VTRS) Narrative? - Yahoo Finance
Unveiling Viatris (VTRS) Q4 Outlook: Wall Street Estimates for Key Metrics - Yahoo Finance
What's in Store for These 5 Medical Companies This Earnings Season? - TradingView
Viatris Stock to Report Q4 Earnings: What's in the Cards? - TradingView
Viatris Inc. (VTRS) Investor Outlook: Navigating a 3.02% Dividend Yield Amidst Healthcare Opportunities - DirectorsTalk Interviews
UBS Cite Efficient Capital Allocation and Rising Profits in Viatris Inc. (VTRS) Upgrade - MSN
Viatris: Deep-Value Pharma With Emerging Growth Catalysts And Strong Cash Generation - Seeking Alpha
Shareholders of Viatris Inc. Should Contact Levi & Korsinsky Bef - GuruFocus
Earnings Preview: Viatris (VTRS) Q4 Earnings Expected to Decline - Finviz
Where is Viatris Inc. (VTRS) headed according to the Street? - MSN
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields - Benzinga
(VTRS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Viagra Maker Wins 'Viagor Power' EU TM Battle - Law360
How Do Investors Really Feel About Viatris Inc? - Benzinga
Why Viatris Inc (VTRS) May Struggle to Outperform: A Look at Fut - GuruFocus
Can Viatris Inc. sustain its profitabilityJuly 2025 Levels & Daily Chart Pattern Signals - mfd.ru
Is Viatris Inc. impacted by rising ratesWeekly Trend Summary & Technical Confirmation Alerts - mfd.ru
Is Viatris (VTRS) Quietly Repositioning Its Deal-Making Strategy With a New Chief Legal Officer? - simplywall.st
Viatris (VTRS) Shares Cross 3% Yield Mark - Nasdaq
Viatris Continues Support of SBP, Celebrates Restoration of 250th Home Damaged by Hurricane Maria - CSRwire
Viatris Inc. stock rises Monday, outperforms market - MSN
JPMorgan Adjusts Price Target on Viatris to $16 From $14, Maintains Neutral Rating - marketscreener.com
Viatris stock hits 52-week high at $15.61 By Investing.com - Investing.com Australia
Chris Davis's Strategic Acquisition of Viatris Inc. Shares - GuruFocus
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
Viatris at a Crossroads: Transitioning from Generic Giant to Specialty Powerhouse - FinancialContent
Viatris stock hits 52-week high at $15.61 - Investing.com
Indiana wins $6.25 million in settlement with pharmaceutical companies - starcitytv.com
Where is Viatris Inc. (VTRS) Headed According to the Street? - Finviz
Viatris Septerna BIO Takeda name new legal chiefs - BioXconomy
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Viatris (VTRS) - The Globe and Mail
Viatris 2022 Sustainability Report: Building Foundations To Advance Diversity, Equity and Inclusion - CSRwire
Why Viatris (VTRS) Stock Is Up Today - The Globe and Mail
Viatris Stock Hits 52-Week High After UBS Buy Rating & $18 Price Target | Market Update 2026News and Statistics - IndexBox
Why Viatris (VTRS) Shares Are Rising Today - Bitget
Viatris gains as UBS upgrades to buy on outlook and pipeline - MSN
Indiana reaches $6.25M settlement with pharmaceutical companies over EpiPen prices - Indianapolis Business Journal
비아트리스 (VTRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
13.03%
1.22%
자본화:
|
볼륨(24시간):